Bioventus Inc. (BVS)
Latest financial period: June 27, 2026
Filed with the SEC: August 5, 2026
Estimated earnings date: November 3, 2026
Profit #720 of 1484 companies
| Jun 26 | Mar 26 | Dec 25 | Sep 25 | |
|---|---|---|---|---|
| ROIC | 10.0% | 7.9% | 7.6% | 4.0% |
Growth #668 of 1484 companies
| Jun 26 | Mar 26 | Dec 25 | Sep 25 | |
|---|---|---|---|---|
| Sales andOCF growth | 38.3% | 49.2% | 24.8% | 25.3% |
Payout #1117 of 1484 companies
| Jun 26 | Mar 26 | Dec 25 | Sep 25 | |
|---|---|---|---|---|
| Shareholderdistributions/ net income | 0% | 0% | 0% | 0% |
Safety #1271 of 1484 companies
| Balance | Stability | |
|---|---|---|
| Equity/assets andOCF stability | 30.2% | 28.8% |
Price #302 of 1484 companies
| Earnings | FCF | |
|---|---|---|
| Earnings andFCF yield | $5.02 | $8.68 |
